Edouard L. Fu

3.8k total citations · 1 hit paper
82 papers, 1.7k citations indexed

About

Edouard L. Fu is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Edouard L. Fu has authored 82 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Nephrology, 32 papers in Cardiology and Cardiovascular Medicine and 19 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Edouard L. Fu's work include Chronic Kidney Disease and Diabetes (24 papers), Diabetes Treatment and Management (18 papers) and Blood Pressure and Hypertension Studies (15 papers). Edouard L. Fu is often cited by papers focused on Chronic Kidney Disease and Diabetes (24 papers), Diabetes Treatment and Management (18 papers) and Blood Pressure and Hypertension Studies (15 papers). Edouard L. Fu collaborates with scholars based in Sweden, Netherlands and United States. Edouard L. Fu's co-authors include Friedo W. Dekker, Juan Jesús Carrero, Kitty J. Jager, Carmine Zoccali, Nicholas C Chesnaye, Vianda S Stel, Giovanni Tripepi, Catherine M. Clase, Merel van Diepen and Marie Evans and has published in prestigious journals such as Annals of Internal Medicine, PLoS ONE and Diabetes Care.

In The Last Decade

Edouard L. Fu

71 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An introduction to inverse probability of treatment weighting in observational research

2021 421 citations Vianda S Stel, Giovanni Tripepi et al. Clinical Kidney Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edouard L. Fu Sweden	23	480	460	365	314	203	82	1.7k
Priya Vart Netherlands	26	496 1.0×	456 1.0×	321 0.9×	567 1.8×	422 2.1×	113	2.3k
Chi-Pang Wen Taiwan	14	932 1.9×	540 1.2×	463 1.3×	466 1.5×	276 1.4×	14	2.5k
Janice P. Lea United States	24	846 1.8×	731 1.6×	176 0.5×	313 1.0×	213 1.0×	67	2.0k
Pawana Sharma United Kingdom	19	243 0.5×	234 0.5×	168 0.5×	358 1.1×	295 1.5×	34	1.6k
Melissa Soohoo United States	28	1.1k 2.2×	226 0.5×	274 0.8×	188 0.6×	312 1.5×	74	1.8k
Jamie P. Traynor United Kingdom	22	994 2.1×	213 0.5×	287 0.8×	448 1.4×	361 1.8×	69	2.0k
Nicholas C Chesnaye Netherlands	22	798 1.7×	252 0.5×	217 0.6×	147 0.5×	249 1.2×	55	2.1k
Geetha Maddukuri United States	11	522 1.1×	155 0.3×	200 0.5×	272 0.9×	246 1.2×	14	1.5k
Marc H. Hemmelder Netherlands	19	532 1.1×	306 0.7×	143 0.4×	132 0.4×	104 0.5×	71	1.2k
Ishir Bhan United States	29	741 1.5×	207 0.5×	388 1.1×	284 0.9×	492 2.4×	74	4.0k

Countries citing papers authored by Edouard L. Fu

Since Specialization

Citations

This map shows the geographic impact of Edouard L. Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edouard L. Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edouard L. Fu more than expected).

Fields of papers citing papers by Edouard L. Fu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edouard L. Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edouard L. Fu. The network helps show where Edouard L. Fu may publish in the future.

Co-authorship network of co-authors of Edouard L. Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Edouard L. Fu. A scholar is included among the top collaborators of Edouard L. Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edouard L. Fu. Edouard L. Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sjölander, Arvid, et al.. (2025). Risk-based referral model to nephrologist specialist care in Stockholm. Nephrology Dialysis Transplantation. 41(1). 102–111.

Fu, Edouard L., Anne‐Laure Faucon, Lesley A. Inker, et al.. (2025). Changing from the CKD-EPI to the EKFC creatinine equation to estimate glomerular filtration rate in adults in a Northern European health system. Nephrology Dialysis Transplantation. 41(2). 275–285.

Walker, Heather, Juan Jesús Carrero, Michael Sullivan, et al.. (2025). Frailty in Adults with CKD and Validation of the Kidney Failure Risk Equation in Frailty Subgroups. Clinical Journal of the American Society of Nephrology. 20(8). 1051–1062.

Tanaka, Shigeru, Alberto Bosi, Edouard L. Fu, et al.. (2025). Kidney Function, Kidney Function Decline, and the Risk of Abdominal Aortic Aneurysm: The Stockholm CREAtinine Measurements (SCREAM) Project. Journal of Vascular Surgery. 81(6). 1530–1530. 1 indexed citations

Fu, Edouard L., Deborah J. Wexler, Sara J. Cromer, et al.. (2024). SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. BMJ. 385. e078483–e078483. 10 indexed citations

Hall, Rasheeda K., Rümeyza Kazancıoğlu, Teerawat Thanachayanont, et al.. (2024). Drug stewardship in chronic kidney disease to achieve effective and safe medication use. Nature Reviews Nephrology. 20(6). 386–401. 9 indexed citations

Xu, Yang, Anne‐Laure Faucon, Marie Evans, et al.. (2024). Hyperkalemia and maintenance of renin–angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors. Nephrology Dialysis Transplantation. 40(5). 956–966. 1 indexed citations

Zoccali, Carmine, Giovanni Tripepi, Vianda S Stel, et al.. (2024). Biomarkers in clinical epidemiology studies. Clinical Kidney Journal. 17(6). sfae130–sfae130. 9 indexed citations

Tanaka, Shigeru, Edouard L. Fu, Kunitoshi Iseki, et al.. (2024). Kidney Function, Kidney Function Decline, and the Risk of Abdominal Aortic Aneurysm: The Stockholm CREAtinine Measurements (SCREAM) Project. European Journal of Vascular and Endovascular Surgery. 69(4). 601–608. 1 indexed citations

10.

Janse, Roemer J., et al.. (2024). Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care. Diabetes Research and Clinical Practice. 213. 111745–111745. 2 indexed citations

11.

Fu, Edouard L., Juan Jesús Carrero, Yingying Sang, et al.. (2024). Association of Low Glomerular Filtration Rate With Adverse Outcomes at Older Age in a Large Population With Routinely Measured Cystatin C. Annals of Internal Medicine. 177(3). 269–279. 9 indexed citations

12.

Fu, Edouard L., Rishi Desai, Julie M. Paik, et al.. (2023). Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study. American Journal of Kidney Diseases. 83(3). 293–305.e1. 12 indexed citations

13.

Fu, Edouard L., Rishi Desai, Julie M. Paik, et al.. (2023). #6667 EFFECTIVENESS AND SAFETY OF APIXABAN, RIVAROXABAN AND WARFARIN IN PATIENTS WITH ADVANCED CKD AND ATRIAL FIBRILLATION: A NATIONWIDE US COHORT STUDY. Nephrology Dialysis Transplantation. 38(Supplement_1).

14.

Fu, Edouard L.. (2023). Target Trial Emulation to Improve Causal Inference from Observational Data: What, Why, and How?. Journal of the American Society of Nephrology. 34(8). 1305–1314. 58 indexed citations

15.

Fu, Edouard L., Andrew S. Levey, Anne‐Laure Faucon, et al.. (2023). #4506 ACCURACY OF NOVEL GFR ESTIMATING EQUATIONS BASED ON CREATININE, CYSTATIN C OR BOTH IN ROUTINE CARE. Nephrology Dialysis Transplantation. 38(Supplement_1). 2 indexed citations

16.

Fu, Edouard L., Elisabetta Patorno, Brendan M. Everett, et al.. (2023). Sodium–glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study. European Heart Journal. 44(24). 2216–2230. 19 indexed citations

17.

Sang, Yingying, Elizabeth Selvin, Alex R. Chang, et al.. (2022). Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel. Diabetes Care. 45(12). 2926–2934. 13 indexed citations

18.

Janse, Roemer J., Edouard L. Fu, Catherine M. Clase, et al.. (2022). Stopping versus continuing renin–angiotensin–system inhibitors after acute kidney injury and adverse clinical outcomes: an observational study from routine care data. Clinical Kidney Journal. 15(6). 1109–1119. 9 indexed citations

19.

Fu, Edouard L., et al.. (2021). Virtual end-of-life care during COVID19 outbreak in a nursing home. Journal of the American Geriatrics Society. 69. 1 indexed citations

20.

Trevisan, Marco, Edouard L. Fu, Karolina Szummer, et al.. (2020). Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. European Heart Journal - Cardiovascular Pharmacotherapy. 7(2). 104–111. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact